title: In-vitro antibacterial activity of cefepime: a multicentre study.
abstract: The antimicrobial activity of cefepime, a new broad-spectrum parenteral cephalosporin, was evaluated in vitro against 1757 recent clinical Gram-positive and Gram-negative isolates. Cefepime was active at low concentrations (MIC50 values < or = 0.06 mg/L and MIC90 values < or = 0.12 mg/L) against non-cephalosporinase-producing Enterobacteriaceae (Escherichia coli, Proteus mirabilis, Salmonella spp. and Shigella spp.). For Klebsiella pneumoniae, MICs were between 0.016 and 16 mg/L; the highest MIC values were observed for extended-spectrum beta-lactamase-producing strains. Against Enterobacteriaceae, such as cephalosporinase producing Enterobacter cloacae, MICs were < or = 0.5 mg/L, but MICs against cephalosporinase hyperproducing strains were generally higher. Ticarcillin-sensitive strains of Pseudomonas aeruginosa were inhibited by cefepime concentrations of 0.5-16 mg/L, while cefepime MICs were 8-64 mg/L for strains resistant to ticarcillin. The cefepime MIC50 value for Haemophilus spp. including many resistant to amoxycillin, was 0.03 mg/L. Against methicillin-sensitive strains of Staphylococcus aureus, cefepime MICs were 0.5-16 mg/L; MICs against methicillin-resistant staphylococci were 16- > 128 mg/L). Against methicillin-sensitive coagulase-negative staphylococci, cefepime MIC values were 0.03-16 mg/L; corresponding values for methicillin-resistant strains were 2-128 mg/L. Streptococci (Groups A, C and G) were sensitive to cefepime with MICs ranging from < or = 0.008-2 mg/L (MIC50, 0.03 mg/L; MIC90, 0.25 mg/L). The activity of cefepime against Group B streptococci and pneumococci were comparable, with MIC50 values of 0.12 and 0.25 mg/L, respectively, and MIC90 values of 0.03 and 0.25 mg/L, respectively. Most enterococci and all Listeria monocytogenes strains had MICs > or = 32 mg/L.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Bactériologie-Virologie-Hygiène, Hôpital H. Mondor, Créteil, France.
authors.forename: J
authors.initials: J
authors.lastname: Duval
authors.forename: C J
authors.initials: CJ
authors.lastname: Soussy
authors.forename: J F
authors.initials: JF
authors.lastname: Acar
authors.forename: E
authors.initials: E
authors.lastname: Bergogne-Bérézin
authors.forename: R
authors.initials: R
authors.lastname: Cluzel
authors.forename: A
authors.initials: A
authors.lastname: Thabaut
authors.forename: P
authors.initials: P
authors.lastname: Courvalin
authors.forename: J J
authors.initials: JJ
authors.lastname: Grès
authors.forename: C
authors.initials: C
authors.lastname: Rollin
mesh_terms: D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000453:epidemiology / Q000382:microbiology; D000077723:Cefepime; D002511:Cephalosporins / Q000494:pharmacology*; D004351:Drug Resistance; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests
chemical_list: D002511:Cephalosporins; D000077723:Cefepime